HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early miglustat therapy in infantile Niemann-Pick disease type C.

Abstract
Niemann-Pick disease type C is a rare inherited cholesterol trafficking disorder, where impaired intracellular lipid transport leads to storage of unesterified cholesterol and glycosphingolipids in many tissues, including the brain. Substrate reduction therapy with miglustat, an iminosugar that inhibits glycosphingolipid synthesis, was proposed to treat Niemann-Pick disease type C, based on evidence of slower disease progression and prolonged survival in animal models. Miglustat was subsequently approved in Europe to treat progressive neurologic manifestations in both children and adults in early 2009, based on clinical study data. We report on the early treatment of two pediatric Niemann-Pick type C patients with miglustat. Patient 1, a 7.5-year-old girl with early-infantile onset, began receiving miglustat at age 7 months. Patient 2, the brother of a girl diagnosed with late-infantile onset Niemann-Pick type C, began receiving miglustat at age 19 months, when he was asymptomatic for neurologic disease. After 7 and 5 years of miglustat therapy, respectively, both patients remain free of neurologic manifestations. These findings suggest that miglustat may be more effective if used to prevent, rather than treat, neurologic manifestations in infantile-onset Niemann-Pick type C.
AuthorsMaja Di Rocco, Andrea Dardis, Annalisa Madeo, Rita Barone, Agata Fiumara
JournalPediatric neurology (Pediatr Neurol) Vol. 47 Issue 1 Pg. 40-3 (Jul 2012) ISSN: 1873-5150 [Electronic] United States
PMID22704015 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Carrier Proteins
  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • Membrane Glycoproteins
  • NPC1 protein, human
  • Niemann-Pick C1 Protein
  • 1-Deoxynojirimycin
  • miglustat
Topics
  • 1-Deoxynojirimycin (analogs & derivatives, therapeutic use)
  • Carrier Proteins (genetics)
  • Child
  • DNA Mutational Analysis
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Longitudinal Studies
  • Membrane Glycoproteins (genetics)
  • Mutation (genetics)
  • Niemann-Pick C1 Protein
  • Niemann-Pick Disease, Type C (drug therapy, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: